Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients

BACKGROUND: Post-transplant hyperuricemia (PTHU), defined as serum uric acid concentration ≥7.0 mg/dL or need for treatment with allopurinol or benzbromarone, reduces long-term allograft survival in kidney transplant recipients. Febuxostat, a new nonpurine selective xanthine oxidase inhibitor, is we...

Descripción completa

Detalles Bibliográficos
Autores principales: Sofue, Tadashi, Inui, Masashi, Hara, Taiga, Nishijima, Yoko, Moriwaki, Kumiko, Hayashida, Yushi, Ueda, Nobufumi, Nishiyama, Akira, Kakehi, Yoshiyuki, Kohno, Masakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933431/
https://www.ncbi.nlm.nih.gov/pubmed/24600205
http://dx.doi.org/10.2147/DDDT.S56597

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933431/
https://www.ncbi.nlm.nih.gov/pubmed/24600205
http://dx.doi.org/10.2147/DDDT.S56597

Ejemplares similares